IP Library Granted Patent US 7,202,231
Granted Patent B2
US 7,202,231 · App. 11/025,661 · Granted Apr 10, 2007

β-Cyclodextrin compositions, and use to prevent transmission of sexually transmitted diseases

Assignee: The Johns Hopkins University School of Medicine
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,202,231
App. No.
11/025,661
Granted
Apr 10, 2007
Kind
B2
Abstract

Methods of reducing the risk of transmission of a sexually transmitted pathogen by contacting the pathogen or cells susceptible to infection by the pathogen with a β-cyclodextrin are provided. Methods for reducing the risk of transmission of a sexually transmitted pathogen to or from a subject by contacting the pathogen or cells susceptible to the pathogen in the subject with a pharmaceutical composition containing a β-cyclodextrin also are provided. Accordingly, pharmaceutical compositions, which include 1) a β-cyclodextrin, which is in an amount that blocks passage of the pathogen through lipid rafts in the membrane of a cell susceptible to the pathogen, and 2) a contraceptive, an agent for treating a sexually transmitted disease, a lubricant, or a combination thereof, are provided, as are composition formulated from a solid substrate that contains an amount of β-cyclodextrin useful for reducing the risk of transmission of a sexually transmitted pathogen.

Claims (20)

1. A method of reducing the risk of transmission of a sexually transmitted pathogen in a human subject, comprising contacting the pathogen or cells susceptible to infection by the pathogen with an effective amount of a composition consisting of a β-cyclodextrin and with at least one active agent other than β cyclodextrin, thereby reducing the risk of transmission of the pathogen.

2. The method of claim 1 , wherein the pathogen is an enveloped virus.

3. The method of claim 2 , wherein the enveloped virus is an immunodeficiency virus, a T lymphotrophic virus or a herpesvirus.

4. The method of claim 2 , wherein the enveloped is a human immunodeficiency virus.

5. The method of claim 2 , wherein the enveloped virus is a Herpes simplex virus.

6. The method of claim 1 , wherein the pathogen is a microbial pathogen.

7. The method of claim 6 , wherein the microbial pathogen is a bacterium, a yeast, or a protozoan.

8. The method of claim 6 , wherein the microbial pathogen is a Chlamydia spp., a Trichomona spp., or a Candida spp.

9. A method of reducing the risk of a human subject becoming infected with a sexually transmitted pathogen, the method comprising contacting the pathogen or cells susceptible to infection by the pathogen in the subject with a an effective amount of pharmaceutical composition consisting of a β-cyclodextrin and in addition with a contraceptive or an antibacterial agent, thereby reducing the risk of the subject becoming infected with the sexually transmitted transmission of the pathogen.

10. The method of claim 9 , wherein the cells susceptible to infection by the pathogen are epithelial cells.

11. The method of claim 10 , wherein the epithelial cells are vaginal epithelial cells or rectal epithelial cells.

12. The method of claim 8 , wherein the pharmaceutical composition is formulated in a solution, a gel, a foam, an ointment, a cream, a paste, or a spray.

13. The method of claim 9 , wherein the pharmaceutical composition is formulated in a suppository, a film, a vaginal disk, or a condom.

14. The method of claim 9 , wherein the β-cyclodextrin is 2-hydroxypropyl-β-cyclodextrin.

15. The method of claim 1 , wherein the active agent is a contraceptive agent.

16. The method of claim 1 , wherein the active agent is an antimicrobial agent.

17. The method of claim 15 , wherein the contraceptive is a spermicide.

18. The method of claim 16 , wherein the antimicrobial agent is an antibiotic.

19. The method of claim 9 , wherein the sexually transmitted pathogen is an enveloped virus or a microbial pathogen.

20. The method of claim 19 , wherein the enveloped virus is an immunodeficiency virus, a T lymphotrophic virus or a herpesvirus.

Assignments (1)
CONFIRMATORY LICENSE Recorded Nov 28, 2017
From: JOHNS HOPKINS UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 044514/0567 →
Continuity (5)
Continuation 0980277900 · Mar 8, 2001
Continuation In Part 0980139300 · Mar 7, 2001
Provisional Application 6026719900 · Feb 7, 2001
Provisional Application 6018778400 · Mar 8, 2000
Related Publication 20050215522A1 · Sep 29, 2005